Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
17 08 2022
17 08 2022
Historique:
received:
15
04
2022
accepted:
05
08
2022
entrez:
17
8
2022
pubmed:
18
8
2022
medline:
20
8
2022
Statut:
epublish
Résumé
Both T cells and B cells have been shown to be generated after infection with SARS-CoV-2 yet protocols or experimental models to study one or the other are less common. Here, we generate a chimeric protein (SpiN) that comprises the receptor binding domain (RBD) from Spike (S) and the nucleocapsid (N) antigens from SARS-CoV-2. Memory CD4
Identifiants
pubmed: 35977933
doi: 10.1038/s41467-022-32547-y
pii: 10.1038/s41467-022-32547-y
pmc: PMC9382605
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Nucleocapsid Proteins
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4831Informations de copyright
© 2022. The Author(s).
Références
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Lancet Infect Dis. 2021 Feb;21(2):e26-e35
pubmed: 33125914
PeerJ. 2020 Oct 16;8:e10234
pubmed: 33088633
Nat Rev Immunol. 2021 Feb;21(2):73-82
pubmed: 33340022
Nat Rev Immunol. 2020 Aug;20(8):457-458
pubmed: 32636479
Eur J Immunol. 2019 Oct;49(10):1457-1973
pubmed: 31633216
Lancet. 2021 Dec 11;398(10317):2126-2128
pubmed: 34871545
Expert Rev Vaccines. 2015 Mar;14(3):447-59
pubmed: 25308798
Cell. 2021 May 27;184(11):2939-2954.e9
pubmed: 33852911
Nature. 2020 Dec;588(7838):498-502
pubmed: 32805734
J Virol. 2020 Jun 16;94(13):
pubmed: 32546606
J Clin Invest. 2020 Oct 1;130(10):5235-5244
pubmed: 32634129
Cell Host Microbe. 2021 Apr 14;29(4):522-528.e2
pubmed: 33789085
Nat Commun. 2021 Nov 25;12(1):6844
pubmed: 34824230
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
Semin Immunol. 2020 Jun;49:101414
pubmed: 33011064
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Vaccine. 2022 Jan 31;40(5):701-705
pubmed: 34953607
Cell. 2020 May 14;181(4):914-921.e10
pubmed: 32330414
Science. 2021 Dec 17;374(6574):eabl9551
pubmed: 34726481
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Nat Immunol. 2021 Jan;22(1):74-85
pubmed: 32999467
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Nature. 2022 Feb;602(7898):682-688
pubmed: 35016197
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Virology. 2021 Mar;555:35-43
pubmed: 33450669
J Immunol. 2021 Mar 1;206(5):931-935
pubmed: 33441437
Emerg Infect Dis. 2022 Feb;28(2):331-337
pubmed: 34876242
Sci Rep. 2021 Jan 28;11(1):2608
pubmed: 33510275
Science. 2021 Dec 24;374(6575):1621-1626
pubmed: 34751595
J Immunol. 2021 Jul 15;207(2):376-379
pubmed: 34193597
Nature. 2020 Jul;583(7818):834-838
pubmed: 32408338
Nat Rev Immunol. 2020 Oct;20(10):615-632
pubmed: 32887954
Cancer Immunol Immunother. 2018 Jul;67(7):1091-1103
pubmed: 29696308
Nature. 2022 Jan;601(7894):617-622
pubmed: 34814158
Mem Inst Oswaldo Cruz. 2020 Oct 23;115:e200342
pubmed: 33111751
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Cell. 2021 Mar 4;184(5):1171-1187.e20
pubmed: 33621484
Sci Rep. 2020 Oct 6;10(1):16561
pubmed: 33024213
Proc Natl Acad Sci U S A. 2022 Feb 1;119(5):
pubmed: 35058348
Nature. 2022 Feb;602(7898):657-663
pubmed: 35016194
Sci Rep. 2021 Jan 21;11(1):2062
pubmed: 33479465
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Sci Immunol. 2021 May 25;6(59):
pubmed: 34035118
Immunology. 2018 Jul;154(3):394-406
pubmed: 29315598
Nature. 2022 Mar;603(7901):488-492
pubmed: 35102311
Nucleic Acids Res. 2019 Jan 8;47(D1):D339-D343
pubmed: 30357391
Sci Adv. 2021 May 28;7(22):
pubmed: 34049881
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
Cell Host Microbe. 2021 Jun 9;29(6):917-929.e4
pubmed: 33984285
Vaccine. 2017 Feb 15;35(7):1001-1007
pubmed: 28111142
J Virol. 2022 Mar 23;96(6):e0218421
pubmed: 35080423
Lancet Infect Dis. 2022 Feb;22(2):174-175
pubmed: 35033232
Nature. 2022 Mar;603(7902):687-692
pubmed: 35062015
PLoS Pathog. 2021 Dec 2;17(12):e1010022
pubmed: 34855916
Cell Host Microbe. 2022 Jan 12;30(1):53-68.e12
pubmed: 34921776
Vaccine. 2017 Dec 4;35(48 Pt B):6620-6626
pubmed: 29079103
Nature. 2021 Nov;599(7883):114-119
pubmed: 34488225
Lancet. 2021 Apr 10;397(10282):1351-1362
pubmed: 33798499
Cell Rep Med. 2021 Feb 16;2(2):100204
pubmed: 33521695
Front Immunol. 2017 Dec 21;8:1897
pubmed: 29312355
J Infect Dis. 2020 Sep 14;222(8):1265-1269
pubmed: 32726417
Annu Rev Immunol. 2016 May 20;34:575-608
pubmed: 27168245
Science. 2021 Mar 26;371(6536):1306-1308
pubmed: 33766871
Nat Med. 2021 Dec;27(12):2136-2143
pubmed: 34728831
Nat Med. 2022 Mar;28(3):472-476
pubmed: 35042228
Viruses. 2021 Feb 12;13(2):
pubmed: 33673067
Cell Rep. 2021 Sep 7;36(10):109664
pubmed: 34450033
Nat Immunol. 2020 Nov;21(11):1327-1335
pubmed: 32839612